Skip to content

ZYVERSA THERAPEUTICS, INC.

ZVSA

CIK 0001859007

← back to feed
Revenue (TTM)
—
Q1 May 2026
Net Income (TTM)
−$26.07M
−165.1% YoY Q1 May 2026
EPS Diluted (TTM)
−$3.97
+50.7% YoY Q1 May 2026
Gross Margin
—
Q1 May 2026
Operating Margin
—
Q1 May 2026
Net Margin
—
Q1 May 2026
Free Cash Flow (TTM)
—
Q1 May 2026
Cash
$213.56K
Q1 May 2026
Total Debt
—
Q1 May 2026
Shares Outstanding
8.1M sh
Q1 May 2026

Revenue & Net Income

EPS (Diluted)

Cash Flow

Revenue Growth (YoY)

No data available for this metric.

Balance Sheet

Cash vs Debt

Recent filings